Tribotec (Czechia)

We herein present a series of hitherto unprecedented seleno-pentlandites (Fe4.5Ni4.5S8-YSeY). By analysing the influence of S/Se exchange on the catalyst structure and activity in the electrochemical hydrogen evolution reaction we herein showcase the potential and limitations of homologous S/Se exchanges within pentlandite HER catalysts.

Health monitoring for rotating machines is investigated through two kinds of mock-up experimental data analysis. One is an anomaly mock-up test of roll bearing type rotating machine. Here, inner ring defect anomaly is simulated and its operating data are measured by both attached type accelerometer sensor and non-attached type microphone. Three kinds of signal pre-processing methods, frequency spectrum, principal component analysis and cepstrum, are applied to discriminate normal and abnormal states using several different classification algorithms, such as adaboost or random forest. Through analysis of their performance with the help of receiver operating characteristic (ROC) curve, the importance of diversified health monitoring methods is discussed. Another mock-up experiment is an accelerated test of roll bearing wear. Here, acoustic emission counts, accelerometer signal and wear particle number in lubricating oil are measured. Using these observation data, we make clear the relationships between deterioration mechanisms of bearing and behaviour of different observations.

IntroductionIL28B polymorphisms are linked to differences in SVR rates in HCV treatment-naÔve patients treated with pegylated interferon (P) and ribavirin (R). REALIZE is a Phase 3 study that compared the efficacy, safety and tolerability of telaprevir (T), with or without a Lead-in (LI), in combination with PR against PR alone in prior treatment-failure patients including relapsers, partial responders and null responders (NR). Both T/PR arms were superior to control in all three patient categories. The relationship between IL28B genotype and SVR was investigated retrospectively.Method527/662 (80%) patients enrolled in REALIZE consented to genetic testing. This represented 72%, 76% and 98% of the total relapsers, partial responders, and NR, respectively. Genotype rs12979860 was determined using a TaqMan allelic discrimination assay validated against Sanger sequencing on 50 independent samples. This was a retrospective study based on patients who consented to genetic testing prior to the discovery of IL28B, thus, sample size was not based on formal statistical considerations.ResultsOverall, 94% were Caucasian and 4% were Black. 18% of patients were IL28B CC, 61% CT and 21% TT. By prior response category, the highest proportion of IL28B TT patients was among prior NR (28%) while the highest frequency of CC patients occurred among prior relapsers (27%). The observed IL28B genotype frequencies indicate that the population was not in Hardy–Weinberg equilibrium (χ2=28, p<0.0001). IL28B genotypes were well balanced across all arms with exception of a higher frequency of TTs in the placebo arm. Since no differences were observed between the two T arms, a pooled analysis is presented.ConclusionDifferences in SVR rates among IL28B CC, CT and TT patients were only evident when the three patient subpopulations were pooled, however, SVR among CT and TT patients were still high. In this retrospective analysis, IL28B genotype did not contribute to outcome prediction in prior treatment-experienced patients treated with a telaprevir-based regimen and thus, may be of limited utility in this setting. OP12 Table 1% SVR (n)Overall PopulationPrior RelapsersPrior Partial RespondersPrior Null RespondersPooled T12/PR48 Arms (N=422)Pbo/PR48 Arm (N=105)Pooled T12/PR48 Arms (N=209)Pbo/PR48 Arm (N=52)Pooled T12/PR48 Arms (N=79)Pbo/PR48 Arm (N=20)Pooled T12/PR48 Arms (N=134)Pbo/PR48 Arm (N=33)IL28B CC79 (76)29 (17)88 (58)33 (12)63 (8)20 (5)40 (10)NA (0)IL28B CT60 (266)16 (58)86 (117)20 (30)58 (57)20 (10)29 (92)6 (18)IL28B TT61 (80)13 (30)85 (34)30 (10)71 (14)0 (5)31 (32)7 (15)